Arbutus Biopharma Corp (I9DN F) stock market data APIs
€2.7456
0(0%)
as of July 11, 2025
Try our APIs with
free plan!
Arbutus Biopharma Corp Financial Data Overview
Price chart is built with
Anychart
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 1 and phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
Prev. Close
2.7456
Open
2.7456
High
2.7456
Low
2.7456
52 wk Range
2.546-4.222
Market Cap
524 M
Shares Outstanding
192 M
Revenue
6 403 K
EPS
-0.13
Beta
1.243
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Arbutus Biopharma Corp data using free add-ons & libraries
Get Arbutus Biopharma Corp Fundamental Data
Arbutus Biopharma Corp Fundamental data includes:
- Net Revenue: 6 403 K
- EBITDA: -66 183 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-14
- EPS/Forecast: 0
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Arbutus Biopharma Corp News
New
Arbutus Biopharma Corporation (NASDAQ:ABUS) Q2 2023 Earnings Call Transcript
Arbutus Biopharma Corporation (NASDAQ:ABUS) Q2 2023 Earnings Call Transcript August 3, 2023 Arbutus Biopharma Corporation misses on earnings expectations. Reported EPS is $-0.1 EPS, expectations were ...
Arbutus Biopharma (ABUS) Reports Q2 Loss, Lags Revenue Estimates
Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.10 per share a year ago. These figures ar...
Arbutus Reports Second Quarter 2023 Financial Results and Corporate Update
Arbutus Biopharma Corporation Regulatory approval received in New Zealand to advance AB-101, our oral PD-L1 inhibitor, into a Phase 1 clinical trial with dosing to begin this quarter AB-729 (imdusir...
Arbutus Biopharma Corporation (NASDAQ:ABUS) has caught the attention of institutional investors who hold a sizeable 38% stake
Key Insights Institutions' substantial holdings in Arbutus Biopharma implies that they have significant influence over the company's share price The top 10 shareholders own 51% of the company Analyst...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
